<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191123</url>
  </required_header>
  <id_info>
    <org_study_id>chenxp008</org_study_id>
    <nct_id>NCT03191123</nct_id>
  </id_info>
  <brief_title>Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor</brief_title>
  <official_title>Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to compare hepatectomy with Transarterial Chemoembolization (TACE)
      for Hepatic Cellular Cancer With Solitary Huge Tumor (≥5cm). All patients will be divided
      into two group.One group will receive hepatic resection, while an another equivalent group
      patients will be treated with Transarterial Chemoembolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver.For
      Barcelona Clinic Liver Cancer (BCLC) stage B patients，especially those with Solitary Huge
      Tumor (≥5cm) ，the better therapy between hepatic resection and transarterial
      chemoembolization remains controversial despite extensive studies。 From now on, we
      prospectively collected patients with solitary huge HCC who received hepatectomy or TACE. Of
      the 200 patients，100 patients were surgically treated and the others underwent TACE。After the
      treatment, patients received routine follow-up with physical examination, serum α-fetoprotein
      (AFP) level and ultrasonography at 3-month intervals for the first year and then every 6
      months.The end of follow-up was determined as either the time of last follow-up (July 2019)
      or death. The overall survival，including 1, 2 and 3-year overall survival rates，will be
      analyse. All data are collected prospectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2016</start_date>
  <completion_date type="Anticipated">July 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate will be evaluated at 3 years after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1 years</time_frame>
    <description>Overall survival rate will be evaluated at 1 year after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival rate will be evaluated at 2 years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rates</measure>
    <time_frame>3 years</time_frame>
    <description>any recurrence detected by CT, MRI and laboratory examination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
    <description>death within 30 days after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Survival Rate</condition>
  <arm_group>
    <arm_group_label>Hepatic resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transarterial Chemoembolization(TACE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic resection</intervention_name>
    <description>The aim of this intervention is to reach curative resection.</description>
    <arm_group_label>Hepatic resection</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>The aim of this intervention is one of the palliative treatment.</description>
    <arm_group_label>Transarterial Chemoembolization(TACE)</arm_group_label>
    <other_name>trial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Hepatic cellular Carcinoma.

          -  Patients with Solitary Huge Tumor (≥5cm）of Hepatic cellular Carcinoma (HCC) detected
             by Serum Alpha Fetoprotein (AFP) and CT or MRI.

          -  Patients without Hepatic vein or bile duct invasion and extrahepatic metastasis.

          -  Patients without surgical contraindication.

          -  Patients with Child A or B liver function and indocyanine green retention rate at
             15min (ICGR15) &lt; 10% before treatment.

          -  Laboratory examination: haemoglobin (Hb)&gt;100g/L, white blood cell (WBC) &gt; 3000/mL,
             blood platelet counts (PLT) &gt; 8×10*10/L before treatment.

          -  Patients without severe esophagogastric varices before treatment.

          -  Patients with HBV，HBV DNA≤100, 000 copy/mL.

          -  All of the patients has written consent for this research.

        Exclusion Criteria:

          -  Patients with multiple tumors or vascular or bile duct invasion or extrahepatic
             metastasis.

          -  Patients with surgical contraindication.

          -  Patients with Child C grade liver function before treatment.

          -  Patients with other malignancy.

          -  .Patients treated with hepatic resection or TACE before this treatment.

          -  Patients with severe esophagogastric varices or refractory ascites or coagulation
             dysfunction before treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ganxun Li, Doctor</last_name>
    <phone>+8615271899935</phone>
    <email>liganxun@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoping Chen, Doctor</last_name>
    <phone>+862783665253</phone>
    <email>chenxp@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatic surgery center, Tong ji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Chen, Doctor</last_name>
      <phone>8602783662851</phone>
      <email>chenxp@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ganxun Li, Doctor</last_name>
      <phone>8615271899935</phone>
      <email>liganxun@hust.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>peng zhu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014 Jul;61(1):82-8. doi: 10.1016/j.jhep.2014.03.012. Epub 2014 Mar 17.</citation>
    <PMID>24650695</PMID>
  </results_reference>
  <results_reference>
    <citation>Metussin A, Patanwala I, Cross TJ. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2015 Mar;62(3):747-8. doi: 10.1016/j.jhep.2014.08.057. Epub 2014 Nov 7.</citation>
    <PMID>25450210</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014 Mar;18(3):555-61. doi: 10.1007/s11605-013-2440-x. Epub 2014 Jan 14.</citation>
    <PMID>24420729</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Hepatic Resection</keyword>
  <keyword>TACE</keyword>
  <keyword>Solitary Huge Tumor</keyword>
  <keyword>Overall Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

